“…Chronic immune activation, chronic inflammation, and progressive depletion of CD4+ T-cells experienced by PLHIV have been associated with the development of cardiovascular and metabolic comorbidities, including coronary plaque development, direct myocardial injury, left ventricular dysfunction, accelerated bone resorption, suppression of bone remodeling, and fractures (Carr, 2008; Hileman, Labbato, Storer, Tangpricha, & McComsey, 2014; Longenecker, Sullivan, & Baker, 2015; McComsey et al, 2010; Stein & Hsue, 2012). Furthermore, certain HIV treatments have been linked to dyslipidemia, insulin resistance, and bone loss, further increasing their risk for the development of comorbid conditions and acute cardiovascular and metabolic health complications (Anastos et al, 2007; Bedimo, Maalouf, Zhang, Drechsler, & Tebas, 2012; Brown et al, 2009; Brown & Qaqish, 2006; Calmy et al, 2013; Carr, 2008; Daria et al, 2011; Hileman et al, 2014; McComsey et al, 2010; Mueller et al, 2010; Mulligan et al, 2012; Ridha, Devitt, Boffito, & Boag, 2011). Compounding the risks is HIV and its treatment.…”